In today’s briefing:
- US Banks – Weekly Balance Sheets Post 13 June Are Out, Strong C&I, Low LLR, LDR Up, CP Growth High
- APAC Healthcare Weekly (June 29)- RemeGen, Innovent, Daiichi, SanBio, Otsuka, Chugai, Glenmark
US Banks – Weekly Balance Sheets Post 13 June Are Out, Strong C&I, Low LLR, LDR Up, CP Growth High
- New weekly data from US banks are now out, the first time since 13 June events, so important
- There remains loan acceleration in total loans and also the important bucket, C&I loans
- LDR expansion good, new CP outstanding data shows a surge in growth rate, new highs
APAC Healthcare Weekly (June 29)- RemeGen, Innovent, Daiichi, SanBio, Otsuka, Chugai, Glenmark
- RemeGen granted exclusive rights to develop and commercialize Telitacicept worldwide (excluding Greater China) to Vor Biopharma for $125M. Innovent Biologics received a first-in-class weight loss drug approval in China.
- Daiichi Sankyo received FDA approval for Datroway for the treatment of certain types of non-small cell lung cancer (NSCLC). SanBio now expects Akuugo approval in H2FY26, instead of Q2FY26.
- Otsuka in-licensed HBM7020 from Harbour BioMed for an upfront payment of $47M and near-term milestones. Glenmark Pharmaceuticals has launched Beigene’s Tevimbra in India for NSCLC.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Data and News
- ✓ Events & Webinars
